Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PhXA41 vs Timolol in Glaucoma or Ocular Hypertension
NCT00751062Phase 3Completed
- Sponsor
- Viatris
- Start
- Nov 1992
- Primary completion
- Dec 1993
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of latanoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Viatris. Primary endpoint: Intraocular Pressure reducing effect at 6 months. Started Nov 1992; status: completed.
02
Drugs
latanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT00751062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00751062.